Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
Reads0
Chats0
TLDR
A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.Abstract:
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions There will be an estimated 181 million new cancer cases (170 million excluding nonmelanoma skin cancer) and 96 million cancer deaths (95 million excluding nonmelanoma skin cancer) in 2018 In both sexes combined, lung cancer is the most commonly diagnosed cancer (116% of the total cases) and the leading cause of cancer death (184% of the total cancer deaths), closely followed by female breast cancer (116%), prostate cancer (71%), and colorectal cancer (61%) for incidence and colorectal cancer (92%), stomach cancer (82%), and liver cancer (82%) for mortality Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality) Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts CA: A Cancer Journal for Clinicians 2018;0:1-31 © 2018 American Cancer Societyread more
Citations
More filters
Journal ArticleDOI
Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma
TL;DR: Higher TMB correlated with poor survival outcomes and might inhibit the immune infiltrates in ccRCC, and a Tumor Mutation Burden Prognostic Index (TMBPI) was constructed from multivariate Cox results and Receiver Operating Characteristic (ROC) curve was drawn to assess the predictive accuracy.
Journal ArticleDOI
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial
Oscar Arrieta,Feliciano Barrón,Laura Alejandra Ramírez-Tirado,Zyanya Lucia Zatarain-Barrón,Andrés F. Cardona,Diego Díaz-García,Masao Yamamoto Ramos,Beatriz Mota-Vega,Amir Carmona,Marco Polo Peralta Álvarez,Yolanda Bautista,Fernando Aldaco,Raquel Gerson,Christian Rolfo,Rafael Rosell +14 more
TL;DR: The combination of pembrolizumab plus docetaxel was well and substantially improved ORR and PFS in patients with advanced NSCLC following platinum-based chemotherapy and no new safety signals were identified.
Journal ArticleDOI
Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer
Min Liu,Zan Tong,Chuanlin Ding,Fengling Luo,Shouzhen Wu,Caijun Wu,Sabrin Albeituni,Liqing He,Xiaoling Hu,David Tieri,Eric C. Rouchka,Michito Hamada,Satoru Takahashi,Andrew A. Gibb,Goetz Kloecker,Huang-Ge Zhang,Michael Bousamra,Bradford G. Hill,Xiang Zhang,Jun Yan +19 more
TL;DR: It is demonstrated that the transcription factor c-Maf is a critical controller for immunosuppressive macrophage polarization and function in cancer and a potential target for effective tumor immunotherapy.
Journal ArticleDOI
Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment
TL;DR: The effective ICD induction mediated by Pd-Dox@TGMs NPs boosted the PD-L1 checkpoint blockade effect, which efficiently improved the infiltration of toxic T lymphocytes at the tumor site and showed excellent tumor treatment effects to both primary and abscopal tumors.
Journal ArticleDOI
Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Milad Ashrafizadeh,Zahra Ahmadi,Neda Mohamadi,Ali Zarrabi,Sara Abasi,Gholamreza Dehghannoudeh,Rosette N. Tamaddondoust,Hashem Khanbabaei,Reza Mohammadinejad,Vijay Kumar Thakur,Vijay Kumar Thakur +10 more
TL;DR: It is demonstrated that how CS functionalized-nanocarriers and CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or genes.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.